Preventative Effect of Mebendazole Against Malignancies in Neurofibromatosis 1

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2020 Jul 12

PMID 32650362

Citations 4

Authors

Verena Staedtke

Tyler Gray-Bethke

Gregory J Riggins

Ren-Yuan Bai

Affiliations

Soon will be listed here.

Abstract

Patients with RASopathy Neurofibromatosis 1 (NF1) are at a markedly increased risk of the development of benign and malignant tumors. Malignant tumors are often recalcitrant to treatments and associated with poor survival; however, no chemopreventative strategies currently exist. We thus evaluated the effect of mebendazole, alone or in combination with cyclooxygenase-2 (COX-2) inhibitors, on the prevention of NF1-related malignancies in a (NPcis) mouse model of NF1. Our in vitro findings showed that mebendazole (MBZ) inhibits the growth of NF1-related malignant peripheral nerve sheath tumors (MPNSTs) through a reduction in activated guanosine triphosphate (GTP)-bound Ras. The daily MBZ treatment of NPcis mice dosed at 195 mg/kg daily, initiated 60 days after birth, substantially delayed the formation of solid malignancies and increased median survival ( < 0.0001). Compared to placebo-treated mice, phosphorylated extracellular signal-regulated kinase (pERK) levels were decreased in the malignancies of MBZ-treated mice. The combination of MBZ with COX-2 inhibitor celecoxib (CXB) further enhanced the chemopreventative effect in female mice beyond each drug alone. These findings demonstrate the feasibility of a prevention strategy for malignancy development in high-risk NF1 individuals.

Citing Articles

Repositioning anthelmintics for the treatment of inflammatory-based pathological conditions.

do Nascimento Rodrigues D, Porto J, Dos Santos I, Filho J, Ferreira P Inflammopharmacology. 2024; 33(2):551-571.

PMID: 39589670 DOI: 10.1007/s10787-024-01605-w.

Conditionally replicative adenovirus as a therapy for malignant peripheral nerve sheath tumors.

Nikrad J, Galvin R, Sheehy M, Novacek E, Jacobsen K, Corbiere S Mol Ther Oncol. 2024; 32(2):200783.

PMID: 38595983 PMC: 10959710. DOI: 10.1016/j.omton.2024.200783.

Spontaneous and Engineered Large Animal Models of Neurofibromatosis Type 1.

Osum S, Watson A, Largaespada D Int J Mol Sci. 2021; 22(4).

PMID: 33669386 PMC: 7920315. DOI: 10.3390/ijms22041954.

Special Issue: "Genomics and Models of Nerve Sheath Tumors".

Hirbe A, Dodd R, Pratilas C Genes (Basel). 2020; 11(9).

PMID: 32882803 PMC: 7563428. DOI: 10.3390/genes11091024.

References

Walrath J, Fox K, Truffer E, Alvord W, Quinones O, Reilly K . Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm Genome. 2009; 20(4):214-23. PMC: 2713021. DOI: 10.1007/s00335-009-9179-4. View

Uusitalo E, Rantanen M, Kallionpaa R, Poyhonen M, Leppavirta J, Yla-Outinen H . Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016; 34(17):1978-86. DOI: 10.1200/JCO.2015.65.3576. View

Lee C, Roh J, Choi J, Kang S, Park I, Chung H . Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer. 2011; 21(4):668-72. DOI: 10.1097/IGC.0b013e3182150d56. View

Wang S, Gao H, Zuo J, Gao Z . Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis. FEBS Open Bio. 2019; 9(2):226-240. PMC: 6356183. DOI: 10.1002/2211-5463.12560. View

Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel M . NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010; 31(6):E1506-18. DOI: 10.1002/humu.21271. View

Koczkowska M, Callens T, Chen Y, Gomes A, Hicks A, Sharp A . Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype-phenotype study in neurofibromatosis type 1. Hum Mutat. 2019; 41(1):299-315. PMC: 6973139. DOI: 10.1002/humu.23929. View

Reilly K, Tuskan R, Christy E, Loisel D, Ledger J, Bronson R . Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc Natl Acad Sci U S A. 2004; 101(35):13008-13. PMC: 516509. DOI: 10.1073/pnas.0401236101. View

Reilly K, Loisel D, Bronson R, McLaughlin M, Jacks T . Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 2000; 26(1):109-13. DOI: 10.1038/79075. View

Upadhyaya M, Huson S, Davies M, Thomas N, Chuzhanova N, Giovannini S . An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 2006; 80(1):140-51. PMC: 1785321. DOI: 10.1086/510781. View

10.

Cuzick J . Preventive therapy for cancer. Lancet Oncol. 2017; 18(8):e472-e482. DOI: 10.1016/S1470-2045(17)30536-3. View

11.

Bai R, Staedtke V, Aprhys C, Gallia G, Riggins G . Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011; 13(9):974-82. PMC: 3158014. DOI: 10.1093/neuonc/nor077. View

12.

Jendrossek V . Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2011; 332(2):313-24. DOI: 10.1016/j.canlet.2011.01.012. View

13.

Jacks T, Shih T, Schmitt E, Bronson R, Bernards A, Weinberg R . Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994; 7(3):353-61. DOI: 10.1038/ng0794-353. View

14.

Kehrer-Sawatzki H, Mautner V, Cooper D . Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017; 136(4):349-376. PMC: 5370280. DOI: 10.1007/s00439-017-1766-y. View

15.

Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V . Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001; 3(1):53-61. PMC: 1505025. DOI: 10.1038/sj.neo.7900127. View

16.

Bai R, Staedtke V, Wanjiku T, Rudek M, Joshi A, Gallia G . Brain Penetration and Efficacy of Different Mebendazole Polymorphs in a Mouse Brain Tumor Model. Clin Cancer Res. 2015; 21(15):3462-3470. PMC: 4526400. DOI: 10.1158/1078-0432.CCR-14-2681. View

17.

Hakozaki M, Tajino T, Konno S, Kikuchi S, Yamada H, Yanagisawa M . Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells. PLoS One. 2014; 9(2):e88035. PMC: 3916395. DOI: 10.1371/journal.pone.0088035. View

18.

Rojnueangnit K, Xie J, Gomes A, Sharp A, Callens T, Chen Y . High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015; 36(11):1052-63. PMC: 5049609. DOI: 10.1002/humu.22832. View

19.

De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F . Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003; 72(5):1288-92. PMC: 1180281. DOI: 10.1086/374821. View

20.

Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks A . Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2018; 21(4):867-876. PMC: 6752285. DOI: 10.1038/s41436-018-0269-0. View